Literature DB >> 12404675

Tianeptine and fluoxetine in major depression: a 6-week randomised double-blind study.

Vladimir Novotny1, Frantisek Faltus.   

Abstract

In a 6-week, multicentre, randomised, double-blind controlled study, tianeptine (37.5 mg/day) and fluoxetine (20 mg/day) were compared for efficacy and safety in 178 patients with major depression. No significant difference was shown between the two drugs, either in terms of efficacy (MADRS, CGI, COVI) or in terms of safety, except for the CGI 'severity of illness' which was lower at the end point with tianeptine than with fluoxetine. The percentages of responders (as defined by a 50% decrease of the MADRS score from baseline to end point) were 75% with tianeptine and 67% with fluoxetine, showing the efficacy of both drugs. In conclusion, both tianeptine and fluoxetine are effective and well-tolerated treatments for major depression. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12404675     DOI: 10.1002/hup.411

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  4 in total

Review 1.  Fluoxetine versus other types of pharmacotherapy for depression.

Authors:  A Cipriani; P Brambilla; T Furukawa; J Geddes; M Gregis; M Hotopf; L Malvini; C Barbui
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

Review 2.  Neurobiological and clinical effects of the antidepressant tianeptine.

Authors:  Siegfried Kasper; Bruce S McEwen
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

3.  Post-traumatic stress disorder in different types of stress (clinical features and treatment).

Authors:  G M Rumyantseva; A L Stepanov
Journal:  Neurosci Behav Physiol       Date:  2008-01

Review 4.  The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation.

Authors:  B S McEwen; S Chattarji; D M Diamond; T M Jay; L P Reagan; P Svenningsson; E Fuchs
Journal:  Mol Psychiatry       Date:  2009-08-25       Impact factor: 15.992

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.